ZYBT Stock Analysis: Buy, Sell, or Hold?
ZYBT - Zhengye Biotechnology Holding Limited Ordinary Shares
$1.95
-0.09 (-4.41%)
âŧ
5d:
+28.29%
30d:
+12.72%
90d:
+124.4%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When ZYBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ZYBT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ZYBT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ZYBT is currently trading at $1.95, which is considered fair relative to its 30-day fair value range of $0.41 to $3.02.
Technical Outlook: Technically, ZYBT is showing sideways momentum. Immediate support is located at $1.49, while resistance sits at $2.20. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: ZYBT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZYBT is showing sideways momentum. Immediate support is located at $1.49, while resistance sits at $2.20. Short-term momentum is weak, with the stock down 4.4% recently.
Market Sentiment: ZYBT scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.41 -
$3.02
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
38.2%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.4%)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.41 -
$3.02
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.49
Resistance Level
$2.20
Current Trend
Sideways
Technical data as of
Aug 24, 2026
Fundamental Context
Revenue Growth (YoY)
-40.9%
Earnings Growth (YoY)
-79.6%
Profit Margin
-60.0%
Share & Embed Analysis
Last updated: August 24, 2026 5:27 PM ET
Data refreshes hourly during market hours. Next update: 6:27 PM
Data refreshes hourly during market hours. Next update: 6:27 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZYBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
